Cyclo Therapeutics Inc (CYTH)

[Lazarus]

Anybody happen to read this - posted last Friday on the Motley Fool?

3 Hiddem Gems in the Healthcare Sector

RELEVANT TO CTDH

Sucampo acquired Vtesse, a privately held rare-disease drugmaker, for $200 million. This was comprised of $170 million in cash on hand and 2.78 million shares of common stock. To repeat, no outside funding was needed, which is a result of its healthy free cash flow. Vtesse brings VTS-270 to the table, a treatment for Niemann-Pick Disease Type C1 that's expected to yield results in mid-2018. Rare disease therapies often bear strong pricing power.

Sporting a single-digit P/E, growing at mid-to-high single-digits, and generating plenty of cash flow, Sucampo could be a sneaky smart healthcare play.